
---
title: '超770家机构调研医疗器械行业 龙头迈瑞医疗获得最多关注'
categories: 
 - 金融
 - 证券时报网
 - 快讯
headimg: 'https://picsum.photos/400/300?random=915'
author: 证券时报网
comments: false
date: Sat, 27 Aug 2022 18:48:00 GMT
thumbnail: 'https://picsum.photos/400/300?random=915'
---

<div>   
<p>证券时报e公司讯，以调研日期口径，近一周机构合计调研上市公司207家。被调研方以医药生物、电子、机械设备板块个股居多，均有20家及以上公司上榜。医疗器械龙头<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ300760" style="color: #2f67d1;text-decoration: none;" code="300760" target="_blank">迈瑞医疗</a>获得最多关注，调研机构合计476家。公司于8月20日发布2022年半年报，引发市场围观。除<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ300760" style="color: #2f67d1;text-decoration: none;" code="300760" target="_blank">迈瑞医疗</a>外，近一周还有其余4家医药生物上市公司获100家以上机构调研，分别为<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ300633" style="color: #2f67d1;text-decoration: none;" code="300633" target="_blank">开立医疗</a>、<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ300294" style="color: #2f67d1;text-decoration: none;" code="300294" target="_blank">博雅生物</a>、<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ002223" style="color: #2f67d1;text-decoration: none;" code="002223" target="_blank">鱼跃医疗</a>和<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ300558" style="color: #2f67d1;text-decoration: none;" code="300558" target="_blank">贝达药业</a>，其中<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ300633" style="color: #2f67d1;text-decoration: none;" code="300633" target="_blank">开立医疗</a>调研机构数量为301家。<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ300760" style="color: #2f67d1;text-decoration: none;" code="300760" target="_blank">迈瑞医疗</a>和<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ300633" style="color: #2f67d1;text-decoration: none;" code="300633" target="_blank">开立医疗</a>两只调研居前的医药器械股合计调研机构超过770家。(数据宝)</p>

                  
</div>
            